Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens
- 22 January 2004
- journal article
- clinical trial
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 20 (4) , 555-563
- https://doi.org/10.1185/030079904125003304
Abstract
SUMMARYBackground: Current recommended durations for treatment of atypical community-acquired pneumonia (CAP) range from 10 to 21 days. However, antibiotics such as the fluoroquinolones may allow for effective, short-course regimens.Objective: This study evaluated the efficacy of 750 mg levofloxacin for 5 days compared to a 500-mg, 10-day levofloxacin regimen for the treatment of atypical CAP.Methods: A randomized, active-controlled, double-blind, multicenter study was conducted within the United States. Of the 528 patients enrolled in the study, 149 were diagnosed with CAP due to Legionella pneumophila, Chlamydia pneumoniae, or Mycoplasma pneumoniae. Patients’ baseline symptoms were re-evaluated on Day 3 of therapy. Clinical efficacy and resolution of CAP symptoms were evaluated at the posttherapy visit (7–14 days after the last dose of active drug).Results: This report represents a subgroup analysis of a previous clinical study. Among the 123 clinically evaluable patients diagnosed with atypical CAP (26...Keywords
This publication has 19 references indexed in Scilit:
- High‐Dose, Short‐Course Levofloxacin for Community‐Acquired Pneumonia: A New Treatment ParadigmClinical Infectious Diseases, 2003
- Factors Associated with Relative Rates of Antimicrobial Resistance amongStreptococcus pneumoniaein the United States: Results from the TRUST Surveillance Program (1998–2002)Clinical Infectious Diseases, 2003
- StandardizingChlamydia pneumoniaeAssays: Recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada)Clinical Infectious Diseases, 2001
- Guidelines for the Management of Adults with Community-acquired PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal AnalysisAntimicrobial Agents and Chemotherapy, 2001
- ONCE A DAY LEVOFLOXACIN IN THE TREATMENT OF MILD TO MODERATE AND SEVERE COMMUNITY-ACQUIRED PNEUMONIA IN ADULTSInfectious Diseases in Clinical Practice, 1998
- A Prediction Rule to Identify Low-Risk Patients with Community-Acquired PneumoniaNew England Journal of Medicine, 1997
- Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical courseThe American Journal of Medicine, 1996
- Serological Diagnosis of Mycoplasma pneumoniae Infections: A Critical Review of Current ProceduresClinical Infectious Diseases, 1993
- The problems of treating atypical pneumoniaJournal of Antimicrobial Chemotherapy, 1993